Dishman Carbogen Amcis Limited Reports Earnings Results for the Full Year Ended March 31, 2022
May 10, 2022 at 11:57 am
Share
Dishman Carbogen Amcis Limited reported earnings results for the full year ended March 31, 2022. For the full year, the company reported sales was INR 21,406.9 million compared to INR 19,120.3 million a year ago. Revenue was INR 21,841.1 million compared to INR 19,504.8 million a year ago. Net income was INR 180.1 million compared to net loss of INR 1,651.3 million a year ago. Basic earnings per share from continuing operations was INR 1.15 compared to basic loss per share from continuing operations of INR 10.53 a year ago. Diluted earnings per share from continuing operations was INR 1.15 compared to diluted loss per share from continuing operations of INR 10.53 a year ago.
Dishman Carbogen Amcis Limited is engaged in offering contract research and manufacturing services (CRAMS), quats, specialty chemicals, Vitamins D3 and its analogues, cholesterols, and disinfectants. The Companyâs segments include CRAMS and Marketable Molecules. The CRAMS segment includes Contract Research Services and Contract Manufacturing Services, which it offers to its customers. Through its CRAMS business, the Company assists drug manufacturers in the development and optimization of processes for novel drug molecules in various stages of the development process. Its Marketable Molecules segment manufactures and supplies intermediates, chemicals, and various products for pharmaceutical, cosmetic and related industries. It has manufacturing and research facilities in India, Switzerland, France, the Netherlands, the United Kingdom and China. Its subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd. and Dishman Carbogen Amcis (Singapore) Pte. Ltd.